Efficacy and Safety of Bisoprolol in Patients with Chronic Obstructive Pulmonary Disease: A Systematic Review and Meta-Analysis

References

• Vogelmeier CF, Criner GJ, Martinez FJ. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report. GOLD Executive Summary. Am J Respir Crit Care Med. 2017;195(5):557–582. doi:10.1164/rccm.201701-0218PP
   PubMed Web of Science ®Google Scholar
• Augusti A, Beasley R, Celli BR, et al. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnoses, management, and prevention of COPD. 2020. Available from: http://www.goldcopd.org. Accessed May 27, 2021.
   Google Scholar
• Kovacs G, Agusti A, Barberà JA, et al. Pulmonary Vascular Involvement in Chronic Obstructive Pulmonary Disease. Is There a Pulmonary Vascular Phenotype? Am J Respir Crit Care Med. 2018;198(8):1000–1011. doi:10.1164/rccm.201801-0095PP
   PubMed Web of Science ®Google Scholar
• Voelkel NF, Natarajan R, Drake JI, Bogaard HJ. Right ventricle in pulmonary hypertension. Compr Physiol. 2011;1(1):525–540. doi:10.1002/cphy.c090008
   PubMed Web of Science ®Google Scholar
• Andrea R, López-Giraldo A, Falces C, et al. Lung function abnormalities are highly frequent in patients with heart failure and preserved ejection fraction. Heart Lung Circ. 2014;23(3):273–279. doi:10.1016/j.hlc.2013.08.003
   PubMed Web of Science ®Google Scholar
• Beghé B, Verduri A, Roca M, Fabbri LM. Exacerbation of respiratory symptoms in COPD patients may not be exacerbations of COPD. Eur Respir J. 2013;41(4):993–995. doi:10.1183/09031936.00180812
   PubMed Web of Science ®Google Scholar
• Roca M, Verduri A, Corbetta L, Clini E, Fabbri LM, Beghé B. Mechanisms of acute exacerbation of respiratory symptoms in chronic obstructive pulmonary disease. Eur J Clin Invest. 2013;43(5):510–521. doi:10.1111/eci.12064
   PubMed Web of Science ®Google Scholar
• Mannino DM, Thorn D, Swensen A, Holguin F. Prevalence and outcomes of diabetes, hypertension and cardiovascular disease in COPD. Eur Respir J. 2008;32(4):962–969. doi:10.1183/09031936.00012408
   PubMed Web of Science ®Google Scholar
• Sharma S, Saluja M, Sharma P. Effectiveness of Convalescent Plasma Therapy in Moderate to Severely Ill Covid-19 Patients. J Assoc Physicians India. 2022;70(4):11–12.
   Google Scholar
• Bazroon AA, Alrashidi NF. Bisoprolol. Treasure Island (FL): StatPearls Publishing; 2023.
   Google Scholar
• Tsutsui H, Momomura S-I, Masuyama T, et al.; CIBIS-J Investigators. Tolerability, Efficacy, and Safety of Bisoprolol vs. Carvedilol in Japanese Patients With Heart Failure and Reduced Ejection Fraction ― The CIBIS-J Trial ―. Circ J. 2019;83(6):1269–1277. doi:10.1253/circj.CJ-18-1199
   PubMed Web of Science ®Google Scholar
• Salpeter SR, Ormiston TM, Salpeter EE. Cardioselective β-Blockers in Patients with Reactive Airway Disease. Ann Intern Med. 2002;137(9):715–725. doi:10.7326/0003-4819-137-9-200211050-00035
   PubMed Web of Science ®Google Scholar
• Etminan M, Jafari S, Carleton B, FitzGerald JM. Beta-blocker use and COPD mortality: a systematic review and meta-analysis. BMC Pulm Med. 2012;12(1):48. doi:10.1186/1471-2466-12-48
   PubMedGoogle Scholar
• Du Q, Sun Y, Ding N, Lu L, Chen Y, Chalmers JD. Beta-blockers reduced the risk of mortality and exacerbation in patients with COPD: a meta-analysis of observational studies. PLoS One. 2014;9(11):e113048. doi:10.1371/journal.pone.0113048
   PubMed Web of Science ®Google Scholar
• Kubota Y, Asai K, Furuse E, et al. Impact of β-blocker selectivity on long-term outcomes in congestive heart failure patients with chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2015;10:515–523. doi:10.2147/COPD.S79942
   PubMed Web of Science ®Google Scholar
• Zvizdic F, Begic E, Mujakovic A, et al.Beta-blocker use in moderate and severe chronic obstructive pulmonary Disease. Med arch. 2019;73(2):72–75. doi:10.5455/medarh.2019.73.72-75.
   PubMedGoogle Scholar
• Salpeter S, Ormiston T, Salpeter E. Cardioselective beta-blockers for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2005;2005(4):Cd003566. doi:10.1002/14651858.CD003566.pub2
   PubMedGoogle Scholar
• Paolillo S, Dell’Aversana S, Esposito I, Poccia A, Perrone Filardi P. The use of β-blockers in patients with heart failure and comorbidities: doubts, certainties and unsolved issues. Eur J Intern Med. 2021;88:9–14. doi:10.1016/j.ejim.2021.03.035
   PubMed Web of Science ®Google Scholar
• Rutten FH. β-Blockers May Reduce Mortality and Risk of Exacerbations in Patients With Chronic Obstructive Pulmonary Disease. Arch Intern Med. 2010;170(10):880–887. doi:10.1001/archinternmed.2010.112
   PubMed Web of Science ®Google Scholar
• Lim KP, Loughrey S, Musk M, Lavender M and Wrobel J. (2017). Beta-blocker under-use in COPD patients. COPD. 2017;12:3041–3046. doi:10.2147/COPD.S144333
   Google Scholar
• Albouaini K, Andron M, Alahmar A, Egred M. Beta-blockers use in patients with chronic obstructive pulmonary disease and concomitant cardiovascular conditions. Int J Chron Obstruct Pulmon Dis. 2007;2(4):535–540.
   PubMedGoogle Scholar
• Chatila WM, Thomashow BM, Minai OA, Criner GJ, Make BJ. Comorbidities in chronic obstructive pulmonary disease. Proc Am Thorac Soc. 2008;5(4):549–555. doi:10.1513/pats.200709-148ET
   PubMedGoogle Scholar
• Yang YL, Xiang ZJ, Yang JH, Wang WJ, Xu ZC, Xiang RL. Association of β-blocker use with survival and pulmonary function in patients with chronic obstructive pulmonary and cardiovascular disease: a systematic review and meta-analysis. Eur Heart J. 2020;41(46):4415–4422. doi:10.1093/eurheartj/ehaa793
   PubMed Web of Science ®Google Scholar
• Higgins JPT, Thomas J, Chandler J, et al., editors. Cochrane Handbook for Systematic Reviews of Interventions. 2nd ed. Chichester (UK): John Wiley & Sons; 2019.
   Google Scholar
• Page MJ, Moher D, Bossuyt PM, et al. PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews. BMJ. 2021;372:160. doi:10.1136/bmj.n160
   PubMed Web of Science ®Google Scholar
• Lv Z, Chen F. The efficacy and safety of bisoprolol in the treatment of chronic obstructive pulmonary disease, pulmonary heart disease, and heart failure patients. Chinese J Clin Ration Drug Use. 2022;15(25):9–12+7.
   Google Scholar
• Wu Y. Observation on the efficacy of bisoprolol in the treatment of chronic obstructive pulmonary disease with pulmonary infection. Chinese J Clin Ration Drug Use. 2020;13(05):49–50.
   Google Scholar
• Liu G, Wang L. Effect of Bisuoluoer on cardiopulmonary function in patients with heart failure combined with COPD after AMI. Med J Liaoning. 2019;33(06):13–15.
   Google Scholar
• Lv C. The effect of bisoprolol on the efficacy and expression of inflammatory factors in patients with chronic obstructive pulmonary disease and heart failure. Clin Res. 2019;27(10):84–85.
   Google Scholar
• Zeng J. The effect of bisoprolol combined with home oxygen therapy on lung function and prognosis in COPD patients. Chronic Pathematol J. 2019;20(08):1260–1262.
   Google Scholar
• Yang L, Yang X, Chen J. The effect of bisoprolol on lung function in elderly patients with coronary heart disease and COPD. Prevention and Treatment of Cardiovascular Disease. 2019;9(23):27–28.
   Google Scholar
• Jin Y. The Effect of Bisoprolol Combined with Carboxymethylestan on Pulmonary Function and Blood Gas Analysis in Patients with Chronic Obstructive Pulmonary Disease. Chinese J Clin Ration Drug Use. 2019;12(11):56.
   Google Scholar
• Zhao M, Wang L. Effects of bisoprolol on cardiopulmonary function and exercise tolerance in patients with acute exacerbation of chronic obstructive pulmonary disease complicated with pulmonary heart disease. Chinese Journal of Heart and Heart Rhythm(Electronic Edition. 2019;7(1):32–34.
   Google Scholar
• Yi S, Yuan C, Yi X. The effect of bisoprolol on resting heart rate and lung function in COPD patients with pulmonary infection. The Medical Forum. 2018;22(05):648–649.
   Google Scholar
• Yuan W, Sun H, Zhang N, Wang D. Effect of Bisoprolol on cardiopulmonary function and quality of life in patients with moderate and severe chronic obstructive pulmonary disease combined with chronic heart failure. Herald Med. 2017;36(10):1161–1164.
   Google Scholar
• Yang H. Effect of Bissolol on cardiopulmonary function and inflammatory factors in patients with chronic obstructive pulmonary disease and heart failure. Chine J Rural Med Pharm. 2017;24(16):20–21.
   Google Scholar
• Wu B. Study on the effect of bisoprolol on the efficacy and expression of related inflammatory media in patients with chronic obstructive pulmonary disease. China Continuing Medical Education. 2017;9(19):159–161.
   Google Scholar
• Ma L, Liu D, Xie Y. Effect of Bisoprolol on Cardiopulmonary Function in Patients with Hypertension and Heart Failure Complicated with Chronic Obstructive Pulmonary Disease. Hebei Med. 2017;23(06):1002–1005.
   Google Scholar
• Zhou H, Liu L, Luo C, Zong K. Efficacy and pulmonary function analysis of pesolo in the treatment of chronic obstructive pulmonary disease with chronic heart failure. Systems Med. 2017;2(01):50–52.
   Google Scholar
• Cai B, Xu S. Effects of Bisorol on exercise tolerance and lung function in simple stable chronic obstructive pulmonary disease. Qingdao Med J. 2017;49(01):50–52.
   Google Scholar
• Hu M, Zhang W. Clinical efficacy of bisoprolol in the treatment of chronic obstructive pulmonary disease and its impact on serum inflammatory factor levels and exercise tolerance. Practical J Cardiac Cerebral Pneumal Vascular Dis. 2016;24(12):138–139.
   Google Scholar
• Wang Y, Jia X, Wang N, Chen L. The effect of bisoprolol on lung function and related inflammatory mediators in patients with chronic obstructive pulmonary disease. J Community Med. 2016;14(20):27–28.
   Google Scholar
• Yang D, Chen B, Lin J, Dai M. The effect of bisoprolol on lung function and expression of related inflammatory neurotransmitters in patients with simple stable chronic obstructive pulmonary disease. Chinese J Clin Ration Drug Use. 2016;9(22):27–28.
   Google Scholar
• Hong S. Clinical analysis of bisoprolol in elderly patients with chronic obstructive pulmonary disease and chronic heart failure. CHINA MED Pharm. 2016;6(11):94–96.
   Google Scholar
• Zhou Z. Clinical study of bisoprolol on elderly patients with chronic obstructive pulmonary disease (COPD) and chronic heart failure (CHF). World Latest Med Information. 2016;16(20):66–67.
   Google Scholar
• Hu X. Effect of Bisoprolol on the Lung Function of Patients with Chronic Obstructive Pulmonary Disease and the Expression of Inflammatory Medium. Med Recapitulate. 2016;22(03):563–565.
   Google Scholar
• Jiang X. Effect of bisoprolol in treatment of chronic obstructive pulmonary disease and pulmonary heart disease in heart failure. Chin Health Stand Manag. 2016;7(03):95–97.
   Google Scholar
• Fang Y. Curative effect and safety requirement of bisoprolol for patients with elderly chronic obstructive pulmonary disease complicated with chronic heart failure. World Latest Med Information. 2015;15(99):22–23.
   Google Scholar
• Xiong J. The effect of bisoprolol on lung function and expression of related inflammatory mediators in patients with chronic obstructive pulmonary disease. Chine J Rural Med Pharm. 2015;22(22):7–8.
   Google Scholar
• Du J. Effects of bisoprolol on lung function and expression of inflammatory mediators in patients with chronic obstructive pulmonary disease.The Chinese. J Clin Pharmacol. 2015.
   Google Scholar
• Li X, Wang G. Evaluation of Bisoprolol in the Treatment of 61 Cases of Stable Chronic Obstructive Pulmonary Disease. China Pharmaceuticals. 2015;24(17):50–51.
   Google Scholar
• Peng H, Xu T, Chang B, Sun Y, Zhong J. The Effect of Bisoprolol on Cardiopulmonary Function in Elderly COPD Patients with CHF. Med J National Defending Forces Southwest China. 2015;25(06):646–648.
   Google Scholar
• Zhang G. Analysis of the application effect of bisoprolol in chronic obstructive pulmonary disease with pulmonary heart disease and heart failure. Modern Diagnosis Treatment. 2014;25(07):1590–1591.
   Google Scholar
• Yuan W. Effect of Bisoprolol on Cardiopulmonary Function in Patients with Chronic Obstructive Pulmonary Disease and Chronic Heart Failure. J Pra Med. 2012;28(19):3280–3282.
   Google Scholar
• Zhang L, Gao P, Fang Y. The prognostic impact of bisoprolol on COPD patients. China Practical Med. 2012;7(18):176–178.
   Google Scholar
• Yu Y. Observation of the Curative Effect and Safety of Bisoprolol on Heart Failure in COPD Cor Pulmonale. J Military Surgeon Southwest China. 2010;12(06):1042–1044.
   Google Scholar
• Pei Y. The application of bisoprolol in chronic obstructive pulmonary disease. Proce Clin Med. 2007;6:415–417.
   Google Scholar
• Mainguy V, Girard D, Maltais F, et al. Effect of bisoprolol on respiratory function and exercise capacity in chronic obstructive pulmonary disease. Am J Cardiol. 2012;110(2):258–263. doi:10.1016/j.amjcard.2012.03.019
   PubMed Web of Science ®Google Scholar
• Hawkins NM, MacDonald MR, Petrie MC, et al. Bisoprolol in patients with heart failure and moderate to severe chronic obstructive pulmonary disease: a randomized controlled trial. Eur J Heart Fail. 2009;11(7):684–690. doi:10.1093/eurjhf/hfp066
   PubMed Web of Science ®Google Scholar
• Ke Y, Xu D, Li M, Wu Z, Huang Y. Effects of bisoprolol in combination with trimetazidine on the treatment of heart failure and concomitant chronic obstructive pulmonary disease. Pak J Med Sci. 2016;32(5):1208–1212. doi:10.12669/pjms.325.10850
   PubMed Web of Science ®Google Scholar
• Chhabra SK, De S. Cardiovascular autonomic neuropathy in chronic obstructive pulmonary disease. Respir Med. 2005;99(1):126–133. doi:10.1016/j.rmed.2004.06.003
   PubMed Web of Science ®Google Scholar
• Rasheedy D, Taha HM. Cardiac autonomic neuropathy: the hidden cardiovascular comorbidity in elderly patients with chronic obstructive pulmonary disease attending primary care settings. Geriatr Gerontol Int. 2016;16(3):329–335. doi:10.1111/ggi.12473
   PubMed Web of Science ®Google Scholar
• Jensen MT, Marott JL, Lange P, et al. Resting heart rate is a predictor of mortality in COPD. Eur Respir J. 2013;42(2):341–349. doi:10.1183/09031936.00072212
   PubMed Web of Science ®Google Scholar
• Schnabel P, Maack C, Mies F, Tyroller S, Scheer A, Böhm M. Binding properties of beta-blockers at recombinant beta1-, beta2-, and beta3-adrenoceptors. J Cardiovasc Pharmacol. 2000;36(4):466–471. doi:10.1097/00005344-200010000-00008
   PubMed Web of Science ®Google Scholar
• Nguyen LP, Omoluabi O, Parra S, et al. Chronic exposure to beta-blockers attenuates inflammation and mucin content in a murine asthma model. Am J Respir Cell Mol Biol. 2008;38(3):256–262. doi:10.1165/rcmb.2007-0279RC
   PubMed Web of Science ®Google Scholar
• Lipworth B, Wedzicha J, Devereux G, Vestbo J, Dransfield MT. Beta-blockers in COPD: time for reappraisal. Eur Respir J. 2016;48(3):880–888. doi:10.1183/13993003.01847-2015
   PubMed Web of Science ®Google Scholar
• Dunzendorfer S, Wiedermann CJ. Modulation of neutrophil migration and superoxide anion release by metoprolol. J Mol Cell Cardiol. 2000;32(6):915–924. doi:10.1006/jmcc.2000.1148
   PubMed Web of Science ®Google Scholar
• Roland M, Bhowmik A, Sapsford RJ, et al. Sputum and plasma endothelin-1 levels in exacerbations of chronic obstructive pulmonary disease. Thorax. 2001;56(1):30–35. doi:10.1136/thorax.56.1.30
   PubMed Web of Science ®Google Scholar
• Lin R, Peng H, Nguyen LP, et al. Changes in beta 2-adrenoceptor and other signaling proteins produced by chronic administration of ‘beta-blockers’ in a murine asthma model. Pulm Pharmacol Ther. 2008;21(1):115–124. doi:10.1016/j.pupt.2007.06.003
   PubMed Web of Science ®Google Scholar
• Hanania NA, Singh S, El-Wali R, et al. The safety and effects of the beta-blocker, nadolol, in mild asthma: an open-label pilot study. Pulm Pharmacol Ther. 2008;21(1):134–141. doi:10.1016/j.pupt.2007.07.002
   PubMed Web of Science ®Google Scholar
• GOLD Report Global Initiative for Chronic Obstructive Lung Disease 2020 Report. Global Initiative for Chronic Obstructive Lung Disease. 2020. Available from: https://goldcopd.org/wp-content/uploads/2019/12/GOLD-2020-FINAL-ver1.2-03Dec19_WMV.pdf. Accessed January 26, 2023.
   Google Scholar
• Darawshy F, Abu Rmeileh A, Kuint R, Goychmann-Cohen P, Fridlender ZG, Berkman N. How Accurate Is the Diagnosis of “Chronic Obstructive Pulmonary Disease” in Patients Hospitalized with an Acute Exacerbation? Medicina (Kaunas). 2023;59(3):632. doi:10.3390/medicina59030632
   PubMed Web of Science ®Google Scholar
• Cuthbert JJ, Pellicori P, Clark AL. Optimal Management of Heart Failure and Chronic Obstructive Pulmonary Disease: clinical Challenges. Int J Gen Med. 2022;15:7961–7975. doi:10.2147/IJGM.S295467
   PubMed Web of Science ®Google Scholar